An early stage biotechnology company developing anti-infective human being monoclonal antibodies.

Related StoriesCaltech experts find antibody that may detect, neutralize HIV viruses in infected patientsNew research offers potential for early intervention to prevent neurodegenerative diseasesG7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion stations ‘Arsanis is building a broad portfolio of anti-infective antibodies against bacterial attacks,’ commented Eszter Nagy, MD, PhD, Co-founder and Chief Scientific Officer of Arsanis. ‘The continued support from FFG’s Basisprogramm is based on the progress of our antibody discovery efforts towards companion diagnostics and monoclonal antibody centered therapeutics against severe infections caused by Staphylococcus aureus and multi-medication resistant Escherichia coli.Waksman is a co-main investigator of the study, which is being conducted in over 25 cardiology clinics across the US. Related StoriesCHOP's Buerger Center for Advanced Pediatric Care celebrates grand openingGlan Clwyd Hospital N Wales spend money on Esaote's G-Scan MRI unit for weight-bearing scanningArsenic publicity during pregnancy may increase risk of infections, respiratory symptoms in childrenStudy Results and Methodology In this prospective observational cohort research, the RSR test was performed on 153 consecutive patients referred for coronary angiography with indicators suggestive of CAD. The RSR tests were executed in a holding area of the catheterization laboratory by an individual examiner blinded to the patient’s scientific data.